Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q92574

UPID:
TSC1_HUMAN

ALTERNATIVE NAMES:
Tuberous sclerosis 1 protein

ALTERNATIVE UPACC:
Q92574; B7Z897; Q5VVN5

BACKGROUND:
The Hamartin protein, identified by its gene symbol TSC1, is implicated as a tumor suppressor and is essential for negatively regulating mTORC1 signaling in response to nutrient and growth factor levels. It facilitates the chaperoning of key proteins, including TSC2 and glucocorticoid receptor NR3C1, by HSP90AA1, and plays a role in preventing the misfolding and degradation of these proteins.

THERAPEUTIC SIGNIFICANCE:
Given Hamartin's critical function in regulating cell growth and its association with significant diseases like Tuberous sclerosis 1 and Lymphangioleiomyomatosis, targeting this protein could lead to innovative treatments for these conditions. The exploration of Hamartin's functions and interactions offers promising avenues for drug discovery and development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.